According to Gram Research analysis, a natural peptide called ST2b found in sweet potato vines reduced blood glucose levels and improved insulin sensitivity in mice with type 2 diabetes by blocking cholesterol production pathways. In laboratory studies, ST2b also improved glucose uptake in human liver cells and normalized fat metabolism. However, these findings are from animal and cell studies only, human trials are needed before this compound could become a diabetes treatment.
Researchers discovered a natural peptide called ST2b from sweet potato vines that may help treat type 2 diabetes by controlling how the body makes cholesterol. In laboratory and animal studies, ST2b improved blood sugar control, reduced insulin levels, and helped the body process fats better. The compound works by stabilizing a protein called INSIG-1, which blocks a master switch in cells that normally tells them to make too much cholesterol. This finding suggests sweet potatoes could become a new source for diabetes treatments or functional foods, though human studies are still needed to confirm these results.
Key Statistics
A 2026 research article published in Biochimica et Biophysica Acta found that ST2b, a nine-amino-acid peptide from sweet potato vines, reduced fasting blood glucose and improved insulin sensitivity in mice with type 2 diabetes induced by high-fat diet and chemical treatment.
In laboratory experiments with human liver cells, the sweet potato-derived peptide ST2b significantly increased glucose uptake in insulin-resistant cells and improved the balance of fat and sugar metabolism.
The ST2b peptide works by stabilizing a protein called INSIG-1, which blocks SREBP-2 (a master control switch for cholesterol production), reducing the harmful fat accumulation in organs that damages metabolism in type 2 diabetes.
The Quick Take
- What they studied: Whether a natural protein fragment from sweet potato vines could help control blood sugar and fat metabolism in type 2 diabetes by blocking cholesterol-making processes in cells
- Who participated: Laboratory experiments used human liver cells and mice with type 2 diabetes induced through diet and chemical treatment. No human participants were included in this research.
- Key finding: The sweet potato peptide ST2b reduced fasting blood glucose levels and improved insulin sensitivity in diabetic mice while normalizing how their bodies processed fats
- What it means for you: This research is early-stage and shows potential, but it’s not yet ready for human use. More studies in people are needed before sweet potato peptides could become a diabetes treatment. It does suggest that natural compounds from foods might help manage diabetes in the future.
The Research Details
Scientists isolated a small protein fragment (called a peptide) named ST2b from sweet potato vines. They tested it in two ways: first in human liver cells grown in dishes to see if it improved glucose uptake and fat metabolism, and second in mice that had been given type 2 diabetes through a combination of a high-fat, high-sugar diet and a chemical injection. The mice received ST2b through their stomachs (like taking medicine by mouth) and researchers measured their blood sugar, insulin levels, and fat metabolism over time.
The researchers also studied exactly how ST2b works at the molecular level. They discovered that ST2b binds to and stabilizes a protein called INSIG-1, which acts like a brake on SREBP-2, a master control switch that tells cells to make cholesterol. By keeping INSIG-1 stable, ST2b prevents SREBP-2 from activating, which reduces the genes that produce cholesterol and helps fix the fat metabolism problems seen in diabetes.
This approach is important because type 2 diabetes involves not just high blood sugar, but also problems with how the body handles fats and cholesterol. By targeting the cholesterol-making pathway, researchers hoped to address multiple problems at once.
Type 2 diabetes affects how the body handles both sugar and fats. Current treatments focus mainly on blood sugar, but many diabetics still have problems with cholesterol and fat buildup in organs. This research matters because it targets a different pathway, the cholesterol-making system, which could help fix multiple problems in diabetes at the same time. Finding natural compounds that work this way could lead to new treatments with fewer side effects than current medications.
This is laboratory and animal research, which is an important first step but has limitations. The study shows the compound works in controlled conditions, but animal models don’t always predict human results. The research was published in a peer-reviewed scientific journal, which means other experts reviewed it. However, no human studies have been done yet, so we don’t know if these results will apply to people. The exact sample sizes for animal experiments weren’t specified in the abstract, which makes it harder to evaluate the strength of the findings.
What the Results Show
In mice with type 2 diabetes, ST2b treatment reduced fasting blood glucose levels (the amount of sugar in the blood when not eating) and lowered serum insulin levels (the amount of insulin hormone in the blood). The compound also improved glucose tolerance, meaning the mice’s bodies handled sugar better after eating. Insulin sensitivity improved, meaning the mice’s cells responded better to insulin signals.
In laboratory dishes using human liver cells that had been made resistant to insulin, ST2b significantly increased glucose uptake, essentially helping the cells take in more sugar from the bloodstream. The compound also improved the overall balance of fats and sugars in the cells’ metabolism.
Beyond blood sugar control, ST2b normalized lipid metabolism (how the body processes fats) and protected metabolic organs like the liver and pancreas from damage. This suggests the compound helps fix multiple problems caused by diabetes, not just high blood sugar.
The research revealed that ST2b works by a specific mechanism: it binds to and stabilizes INSIG-1, a protein that normally gets broken down in cells. By keeping INSIG-1 stable, ST2b prevents it from being degraded. This allows INSIG-1 to interact with another protein called SCAP, which blocks SREBP-2 (the master switch for cholesterol production) from becoming active. When SREBP-2 can’t activate, cells produce fewer cholesterol-synthesis genes, reducing the harmful buildup of cholesterol and fats that damages organs in diabetes.
Previous research has shown that SREBP-2 is overactive in type 2 diabetes, leading to excessive cholesterol production and fat accumulation in organs, a condition called lipotoxicity. This damages the pancreas and liver. Scientists have known that blocking the SREBP pathway could help, but finding natural, specific compounds that do this safely has been difficult. This research adds to growing evidence that natural peptides from plants might offer new ways to target these pathways, potentially with fewer side effects than synthetic drugs.
This study only tested ST2b in laboratory cells and mice, not in humans. Animal models of diabetes don’t perfectly mimic human disease, so results may not translate directly to people. The study didn’t compare ST2b to existing diabetes medications, so we don’t know how it stacks up against current treatments. The long-term safety of ST2b in animals wasn’t discussed. Additionally, the study doesn’t address how much of this peptide a person would need to consume from sweet potatoes, or whether eating sweet potatoes would deliver enough of the compound to have these effects. More research is needed to determine if this could become a practical treatment.
The Bottom Line
This research is too early-stage to recommend ST2b as a diabetes treatment. It shows promise in laboratory and animal studies, but human clinical trials are essential before any medical recommendations can be made. For now, people with type 2 diabetes should continue following their doctor’s treatment plans. While this research suggests sweet potatoes may have beneficial compounds, eating sweet potatoes alone is not a substitute for diabetes medication or lifestyle changes. Confidence level: Low (animal studies only).
People with type 2 diabetes or those at risk for it should be aware of this research as a potential future option. Researchers studying natural compounds for metabolic diseases should find this work relevant. Food scientists and pharmaceutical companies developing functional foods or new medications should pay attention. However, this research doesn’t yet apply to anyone’s current treatment decisions. People should not change their diabetes management based on this study.
If this research progresses normally, human clinical trials would likely begin within 2-5 years. Even if trials are successful, it would take several more years for regulatory approval and development into a treatment. A realistic timeline for a potential product reaching patients would be 7-10 years or more from now. In the meantime, this remains a promising research direction rather than an available option.
Frequently Asked Questions
Can eating sweet potatoes help treat type 2 diabetes?
Research shows a peptide from sweet potato vines may help in laboratory and animal studies, but human trials haven’t been done yet. Eating sweet potatoes is nutritious and part of a healthy diet, but it’s not a diabetes treatment. Continue following your doctor’s treatment plan.
How does the ST2b peptide from sweet potatoes work?
ST2b stabilizes a protein called INSIG-1, which blocks SREBP-2, a master switch that tells cells to make cholesterol. By reducing cholesterol production, it helps fix the fat metabolism problems that damage organs in type 2 diabetes.
When will this sweet potato treatment be available for people?
This research is still in early stages with only animal and laboratory studies completed. Human clinical trials would need to happen first, which typically takes 7-10 years or more. It’s too early to know if this will become an available treatment.
Is this better than current diabetes medications?
The study didn’t compare ST2b to existing diabetes drugs, so we can’t say yet. This research is promising but preliminary. Current medications have been tested in humans and proven safe and effective, continue using them as prescribed by your doctor.
Should I change my diet based on this sweet potato research?
Sweet potatoes are nutritious and can be part of a healthy diabetes diet, but this research doesn’t show eating them will treat diabetes. Focus on your doctor’s recommendations for blood sugar management, medication, and overall diet rather than relying on this early-stage research.
Want to Apply This Research?
- Users could track their daily sweet potato consumption (in grams or servings) alongside their blood sugar readings to monitor any patterns, though they should understand this is observational only and not a replacement for medical treatment.
- Users interested in this research could add sweet potato to their regular meals and track how they feel and their energy levels, while continuing to monitor blood sugar as directed by their doctor. They could set a goal like ‘Include sweet potato in 3 meals per week’ and log when they do.
- Long-term, users could maintain a food diary noting sweet potato intake and correlate it with their regular blood sugar monitoring (as prescribed by their healthcare provider). They should also track any changes in how they feel, energy levels, and weight, while understanding that any benefits would be supplementary to their prescribed diabetes management plan.
This research is preliminary and based on laboratory and animal studies only. No human clinical trials have been conducted. These findings should not be used to guide personal medical decisions or replace prescribed diabetes treatments. Anyone with type 2 diabetes should continue following their healthcare provider’s treatment plan, including medications, diet, and exercise recommendations. Do not attempt to use sweet potato extracts or peptides as a diabetes treatment without consulting your doctor. This article is for educational purposes only and is not medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
